News

Article September 9, 2024

Hope for Alzheimer’s: A Conversation with Gladstone’s Lennart Mucke

Mucke, director of the Gladstone Institute of Neurological Disease, discusses what's next for Alzheimer’s research, the role of nonprofit research in developing new therapies, and why he's more hopeful than ever for a future where neurodegenerative diseases are fully treatable—and even preventable.

Alzheimer’s Disease Neurological Disease Mucke Lab Aging

Gladstone in the News September 8, 2023

In Alzheimer Brain, Can Synaptic Pruning Be Good?

Alzforum—Loss of synapses in the brain is associated with progression of Alzheimer’s disease. However, a new study led by Lennart Mucke, director of the Gladstone Institute of Neurological Disease, shows that in mice, a mutation associated with increased risk of Alzheimer’s disease results in an excess of synapses. In conjunction with recent work from a few other groups, this suggests that removal of synapses may actually play a protective role against Alzheimer’s, at least early in the disease process.

Gladstone Experts Alzheimer’s Disease Neurological Disease Mucke Lab

Article April 27, 2022

Zeroing in on a New Treatment for Autism and Epilepsy

Gladstone scientists show that reducing levels of the protein tau soon after birth can prevent these conditions in an experimental model

News Release Research (Publication) Epilepsy Neurological Disease Mucke Lab

Article October 26, 2021

Alzheimer’s Disease May Cause Vicious Circle between Brain Network and Immune Cell Dysfunctions

Gladstone scientists identified treatments to block subtle epileptic activity and chronic brain inflammation in a mouse model of Alzheimer’s disease

News Release Research (Publication) Alzheimer’s Disease Neurological Disease Mucke Lab

Article October 19, 2021

Maintaining Balance in the Brain

Gladstone scientists help explain how reducing the protein tau can prevent abnormal brain activity associated with Alzheimer’s disease, autism, and epilepsy

News Release Research (Publication) Alzheimer’s Disease Epilepsy Neurological Disease Mucke Lab

Article October 18, 2021

Gladstone Neuroscience Researcher Elected to the National Academy of Medicine

Lennart Mucke is recognized for his pioneering discoveries in research on Alzheimer’s disease and related disorders

Awards News Release Neurological Disease Mucke Lab

Article June 16, 2021

CNDAP Partners with Takeda to Develop New Therapies for Alzheimer’s Disease and Related Brain Disorders

A research collaboration to target the protein tau with small molecules

Business Development News Release Alzheimer’s Disease Neurological Disease Mucke Lab

Article April 21, 2021

Meet Gladstone: Randi Mott

Randi Mott was born in New Jersey but grew up in Florida. She has an extensive orchid collection and would like to meet Austrian zoologist Paul Pfurtscheller

EAsAAs Profile Mucke Lab

Article March 26, 2021

Leading the Way to Better Treatments for People with Epilepsy

Gladstone researchers harness unique tools and perspectives to study life-threatening seizures that lack a cure

Gladstone Experts Epilepsy Center for Neurovascular Brain Immunology Neurological Disease Akassoglou Lab Mucke Lab Palop Lab Paz Lab Deep Dive

Article October 14, 2020

Young Scientists Committed to Finding Treatments for Neurodegenerative Diseases

The 2020 Berkelhammer Scholars break new ground in research on dementias, Parkinson’s disease, and neuropsychiatric disorders

Donor Stories Parkinson’s Disease Alzheimer’s Disease Dementia Neurological Disease Akassoglou Lab Kreitzer Lab Mahley Lab Mucke Lab Nakamura Lab

Video June 19, 2020

Current and Future Strategies to Treat and Prevent Alzheimer’s Disease

With an estimated 44 million diagnosed with Alzheimer’s disease worldwide, research is moving quickly to better understand the disease.

Gladstone Experts Alzheimer’s Disease Neurological Disease Mahley Lab Mucke Lab

Gladstone in the News April 12, 2020

Bay Area Labs Fighting Coronavirus, Sometimes Leaving Regular Work Aside

San Francisco Chronicle—The COVID-19 pandemic has disrupted many industries, including biomedical research. Senior Investigators Warner Greene and Lennart Mucke describe how some labs have shifted the focus of their work to address the current crisis, while others have been forced to put important work on pause.

Research (Publication) COVID-19 Greene Lab Mucke Lab

Gladstone in the News March 3, 2020

Autism Symptoms Improved in Mice by Reducing Alzheimer’s Disease Protein

GEN—Genetic Engineering and Biotechnology News reports on a recent study from the lab of Lennart Mucke that shows how reducing levels of Tau, a protein associated with Alzheimer’s disease, could prevent some symptoms of autism.

Gladstone Experts Mucke Lab

Gladstone in the News March 2, 2020

Alzheimer’s Protein Turns up as Potential Target for Autism Treatments

Spectrum—Lowering the levels of a protein called tau, best known for its involvement in Alzheimer’s disease, eases autism-like traits in mice, according to a study from the lab of Lennart Mucke.

Gladstone Experts Mucke Lab

Gladstone in the News March 2, 2020

Suppressing Alzheimer’s Protein Prevents Autism Symptoms in Mouse Model

Technology Networks—A recent study from Senior Investigator Lennart Mucke and his team show how a protein related to Alzheimer’s disease could play a role in autism.

Gladstone Experts Mucke Lab